|
DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Change in Forecast Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU) Dermapharm Holding SE raises EBITDA forecast for the full year 2021 Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the business development in November on the basis of the preliminary figures in its Management Board meeting today and decided to adjust the forecast for the financial year 2021. Accordingly, the Executive Board now expects Group EBITDA1 to grow by 70 to 75 percent compared to the previous year (previously: 50 to 60 percent). In addition, the Executive Board confirms the revenue forecast for the 2021 financial year of 15 to 20 percent growth compared to the same period of the previous year. 1 EBITDA is an alternative performance indicator that is not defined according to international accounting standards. The Company uses these metrics to allow for better comparability of the business over time and within the industry. EBITDA is defined as earnings before interest, taxes, depreciation and amortisation (see Dermapharm page 31, Annual Report 2020). >End of the Ad hoc announcement< Contact Investor Relations & Corporate Communications
16-Dec-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Dermapharm Holding SE |
| Lil-Dagover-Ring 7 | |
| 82031 Grünwald | |
| Germany | |
| Phone: | +49 (0)89 64 86-0 |
| E-mail: | ir@dermapharm.com |
| Internet: | ir.dermapharm.de |
| ISIN: | DE000A2GS5D8 |
| WKN: | A2GS5D |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1258883 |
| End of Announcement | DGAP News Service |
|
|
1258883 16-Dec-2021 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
